Successful rituximab-CHOP treatment of systemic lupus erythematosus associated with diffuse large B-cell non-Hodgkin lymphoma

Zs Simon, T. Tarr, Zs Ress, L. Gergely, E. Kiss, A. Illés

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

The authors discuss the case of a 76-year-old female patient who has been suffering from subacute cutaneous lupus erythematosus since 1983. In 1999 she was diagnosed with systemic lupus erythematosus (SLE) based on her symptoms of malar rash, polyarthritis, leukopenia, autoimmune hemolytic anemia and positive anti-DNA antibody test. For this she received methylprednisolone and cyclophosphamide. After 3 years of remission, symptoms of cutaneous vasculitis appeared in 2004, which transitionally responded to treatment with azathioprin and methylprednisolone. Her cutaneous symptoms, however, progressed quickly along with generalized lymphadenopathy, splenomegaly and thrombocytopenia. Immunohistological evaluation of the lymph node biopsy showed diffuse large B-cell lymphoma. She developed complete remission after treatment with six-cycle R-CHOP (rituximab, and reduced doses of cyclophosphamide, vincristin, adriablastin, methylprednisolone). SLE became inactive and her symptoms of vasculitis resolved. The authors are bringing attention to one of the possible late complications of systemic lupus, and also underscoring that treatment with rituximab (+CHOP) was beneficial not only for the lymphoma but the SLE as well.

Original languageEnglish
Pages (from-to)179-183
Number of pages5
JournalRheumatology International
Volume28
Issue number2
DOIs
Publication statusPublished - Dec 2007

Fingerprint

Methylprednisolone
B-Cell Lymphoma
Systemic Lupus Erythematosus
Non-Hodgkin's Lymphoma
Vasculitis
Cyclophosphamide
Cutaneous Lupus Erythematosus
Autoimmune Hemolytic Anemia
Skin
Lymphoma, Large B-Cell, Diffuse
Antinuclear Antibodies
Splenomegaly
Leukopenia
Exanthema
Thrombocytopenia
Doxorubicin
Arthritis
Lymphoma
Therapeutics
Lymph Nodes

Keywords

  • Biological therapy
  • DLBCL
  • Lupus
  • Non-Hodgkin lymphoma
  • Rituximab

ASJC Scopus subject areas

  • Rheumatology

Cite this

@article{e4a1fd6695e7444eaf3b4deeb08d6b60,
title = "Successful rituximab-CHOP treatment of systemic lupus erythematosus associated with diffuse large B-cell non-Hodgkin lymphoma",
abstract = "The authors discuss the case of a 76-year-old female patient who has been suffering from subacute cutaneous lupus erythematosus since 1983. In 1999 she was diagnosed with systemic lupus erythematosus (SLE) based on her symptoms of malar rash, polyarthritis, leukopenia, autoimmune hemolytic anemia and positive anti-DNA antibody test. For this she received methylprednisolone and cyclophosphamide. After 3 years of remission, symptoms of cutaneous vasculitis appeared in 2004, which transitionally responded to treatment with azathioprin and methylprednisolone. Her cutaneous symptoms, however, progressed quickly along with generalized lymphadenopathy, splenomegaly and thrombocytopenia. Immunohistological evaluation of the lymph node biopsy showed diffuse large B-cell lymphoma. She developed complete remission after treatment with six-cycle R-CHOP (rituximab, and reduced doses of cyclophosphamide, vincristin, adriablastin, methylprednisolone). SLE became inactive and her symptoms of vasculitis resolved. The authors are bringing attention to one of the possible late complications of systemic lupus, and also underscoring that treatment with rituximab (+CHOP) was beneficial not only for the lymphoma but the SLE as well.",
keywords = "Biological therapy, DLBCL, Lupus, Non-Hodgkin lymphoma, Rituximab",
author = "Zs Simon and T. Tarr and Zs Ress and L. Gergely and E. Kiss and A. Ill{\'e}s",
year = "2007",
month = "12",
doi = "10.1007/s00296-007-0400-z",
language = "English",
volume = "28",
pages = "179--183",
journal = "Rheumatology International",
issn = "0172-8172",
publisher = "Springer Verlag",
number = "2",

}

TY - JOUR

T1 - Successful rituximab-CHOP treatment of systemic lupus erythematosus associated with diffuse large B-cell non-Hodgkin lymphoma

AU - Simon, Zs

AU - Tarr, T.

AU - Ress, Zs

AU - Gergely, L.

AU - Kiss, E.

AU - Illés, A.

PY - 2007/12

Y1 - 2007/12

N2 - The authors discuss the case of a 76-year-old female patient who has been suffering from subacute cutaneous lupus erythematosus since 1983. In 1999 she was diagnosed with systemic lupus erythematosus (SLE) based on her symptoms of malar rash, polyarthritis, leukopenia, autoimmune hemolytic anemia and positive anti-DNA antibody test. For this she received methylprednisolone and cyclophosphamide. After 3 years of remission, symptoms of cutaneous vasculitis appeared in 2004, which transitionally responded to treatment with azathioprin and methylprednisolone. Her cutaneous symptoms, however, progressed quickly along with generalized lymphadenopathy, splenomegaly and thrombocytopenia. Immunohistological evaluation of the lymph node biopsy showed diffuse large B-cell lymphoma. She developed complete remission after treatment with six-cycle R-CHOP (rituximab, and reduced doses of cyclophosphamide, vincristin, adriablastin, methylprednisolone). SLE became inactive and her symptoms of vasculitis resolved. The authors are bringing attention to one of the possible late complications of systemic lupus, and also underscoring that treatment with rituximab (+CHOP) was beneficial not only for the lymphoma but the SLE as well.

AB - The authors discuss the case of a 76-year-old female patient who has been suffering from subacute cutaneous lupus erythematosus since 1983. In 1999 she was diagnosed with systemic lupus erythematosus (SLE) based on her symptoms of malar rash, polyarthritis, leukopenia, autoimmune hemolytic anemia and positive anti-DNA antibody test. For this she received methylprednisolone and cyclophosphamide. After 3 years of remission, symptoms of cutaneous vasculitis appeared in 2004, which transitionally responded to treatment with azathioprin and methylprednisolone. Her cutaneous symptoms, however, progressed quickly along with generalized lymphadenopathy, splenomegaly and thrombocytopenia. Immunohistological evaluation of the lymph node biopsy showed diffuse large B-cell lymphoma. She developed complete remission after treatment with six-cycle R-CHOP (rituximab, and reduced doses of cyclophosphamide, vincristin, adriablastin, methylprednisolone). SLE became inactive and her symptoms of vasculitis resolved. The authors are bringing attention to one of the possible late complications of systemic lupus, and also underscoring that treatment with rituximab (+CHOP) was beneficial not only for the lymphoma but the SLE as well.

KW - Biological therapy

KW - DLBCL

KW - Lupus

KW - Non-Hodgkin lymphoma

KW - Rituximab

UR - http://www.scopus.com/inward/record.url?scp=36148970430&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=36148970430&partnerID=8YFLogxK

U2 - 10.1007/s00296-007-0400-z

DO - 10.1007/s00296-007-0400-z

M3 - Article

C2 - 17703309

AN - SCOPUS:36148970430

VL - 28

SP - 179

EP - 183

JO - Rheumatology International

JF - Rheumatology International

SN - 0172-8172

IS - 2

ER -